found that HCC with high expression of PD-L1, VEGFR and infiltrating CD8+ T cell had better benefit from atezolizumab plus bevacizumab therapy than monotherapy (107), indicating that HCC patients with these features probably appropriate to combined immunotherapy. This evidence concerns the gene KDR and hepatocellular carcinoma.